Par Drugs & Chemicals Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Signal Improved Price Attractiveness

As of 19 Feb 2026, Par Drugs & Chemicals Ltd trades at a P/E ratio of 9.03, a figure that remains well below the industry heavyweights and peers, many of whom are classified as expensive or very expensive. This P/E level indicates that the stock is valued attractively relative to its earnings, especially when compared to companies like Stallion India and Sanstar, which sport P/E ratios of 52.39 and 83.72 respectively. The company’s price-to-book value stands at 1.27, reinforcing the notion that the stock is reasonably priced in relation to its net asset value.

Further valuation multiples such as EV to EBIT (6.79) and EV to EBITDA (5.41) also underscore the stock’s relative affordability. These multiples are significantly lower than those of peers like Platinum Industrials (EV/EBITDA of 21.46) and Titan Biotech (32.12), highlighting Par Drugs & Chemicals’ comparatively conservative market valuation.

Financial Performance and Quality Metrics

Par Drugs & Chemicals boasts a robust ROCE of 22.22%, indicating efficient capital utilisation and operational profitability. Its return on equity (ROE) of 14.05% further supports the company’s ability to generate shareholder value. However, the PEG ratio remains at zero, reflecting either a lack of earnings growth or data unavailability, which warrants cautious interpretation.

Despite these positive fundamentals, the company’s Mojo Score has deteriorated to 48.0, with a downgrade in Mojo Grade from Hold to Sell as of 18 Feb 2026. This downgrade reflects concerns over momentum and other qualitative factors that may be weighing on investor sentiment.

Comparative Industry Valuation Landscape

Within the Chemicals & Petrochemicals sector, Par Drugs & Chemicals stands out for its attractive valuation. Several peers are trading at significantly higher multiples, with companies like Sanstar and Stallion India labelled as very expensive. Meanwhile, a few firms such as I G Petrochems and Gulshan Polyols are rated very attractive, though some of these are loss-making or have different operational profiles.

For instance, I G Petrochems is classified as very attractive but is loss-making, which contrasts with Par Drugs & Chemicals’ profitable status. This distinction is crucial for investors seeking stable earnings alongside valuation appeal.

Stock Price Movement and Market Capitalisation

Par Drugs & Chemicals closed at ₹102.10 on 19 Feb 2026, up 5.74% from the previous close of ₹96.56. The stock’s 52-week trading range spans from ₹81.01 to ₹149.35, indicating a significant volatility band. The current market capitalisation grade is 4, suggesting a mid-sized market cap that may influence liquidity and institutional interest.

Returns Analysis: A Mixed Picture Against Sensex Benchmarks

Examining returns over various time horizons reveals a mixed performance. Over the past week, the stock marginally outperformed the Sensex with a 0.42% gain versus a 0.52% decline in the benchmark. The one-month return is particularly strong at 10.58%, far exceeding the Sensex’s 0.49% rise.

However, longer-term returns paint a more challenging picture. The stock has declined 28.04% over the past year and 31.5% over three years, while the Sensex gained 12.53% and 43.89% respectively over the same periods. Despite this, the five-year return of 205.46% significantly outpaces the Sensex’s 70.77%, highlighting the stock’s strong performance in earlier years.

Investment Implications and Outlook

The recent upgrade in valuation grade from very attractive to attractive suggests that while the stock remains reasonably priced, some of the extreme undervaluation has moderated. Investors should weigh this improved valuation against the company’s mixed momentum signals and recent downgrade in Mojo Grade.

Given the strong ROCE and reasonable P/E and P/BV ratios, Par Drugs & Chemicals may appeal to value-oriented investors seeking exposure to the Chemicals & Petrochemicals sector at a discount to peers. However, the stock’s recent underperformance relative to the Sensex over the medium term and the downgrade to a Sell rating indicate caution is warranted.

Conclusion: Valuation Gains Tempered by Momentum Concerns

Par Drugs & Chemicals Ltd’s shift in valuation parameters reflects a stock that has become more fairly priced after a period of undervaluation. Its P/E of 9.03 and P/BV of 1.27 place it favourably against many sector peers, while its strong ROCE and ROE metrics underpin operational strength.

Nonetheless, the downgrade in Mojo Grade to Sell and the stock’s underwhelming medium-term returns relative to the Sensex suggest that investors should approach with measured expectations. The company’s valuation attractiveness is a positive, but momentum and broader market factors may limit near-term upside.

For investors seeking exposure to the Chemicals & Petrochemicals sector, Par Drugs & Chemicals offers a compelling value proposition, but it is prudent to consider alternative opportunities identified through comprehensive multi-parameter analyses.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today